Colon-Targeted Drug Delivery Systems for Localized Treatment of Inflammatory Bowel Disease

Achal Pravin Patmas[1], Dipali Hamde[2]

[1]M. Pharmacy Student at the Department of Pharmaceutics, Dr. Vedprakash Patil College of Pharmacy, Chh. Sambhajinagar, Maharashtra, India

[2]Associate Professor at Department of Pharmaceutics, Dr. Vedprakash Patil College of Pharmacy, Chh. Sambhajinagar, Maharashtra, India.

***Abstract*—Inflammatory bowel disease (IBD), encompassing Crohn's Disease and Ulcerative Colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract. Conventional systemic therapies often result in suboptimal drug concentrations at the inflamed colonic mucosa and may cause significant adverse effects. Colon-targeted drug delivery systems (CTDDS) have emerged as a promising strategy to enhance therapeutic efficacy while minimizing systemic exposure. These systems exploit the unique physiological characteristics of the colon, including pH variations, transit time, microbial flora, and enzymatic activity, to achieve site-specific drug release. This review discusses the pathophysiology of IBD, the rationale for colon targeting, various colon-targeted delivery approaches, recent advances in nanotechnology-based systems, and current challenges and future perspectives in the field.**

***Index Terms*—Inflammatory bowel disease, colon-targeted drug delivery, pH-sensitive systems, polysaccharides.**

I. INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of the gastrointestinal tract mainly comprising Crohn’s disease and ulcerative colitis. These disorders are characterized by abdominal pain, diarrhea, rectal bleeding, weight loss, and mucosal inflammation, significantly affecting patient quality of life and increasing healthcare burden worldwide.[1] The exact etiology of IBD remains unclear; however, genetic susceptibility, immune dysregulation, environmental factors, intestinal microbiota imbalance, and inflammatory mediators are considered major contributing factors in disease progression.[2] Conventional oral drug delivery systems used in the treatment of IBD often suffer from poor site specificity, premature drug release, reduced bioavailability, and systemic adverse effects due to absorption in the upper gastrointestinal tract. Therefore, the development of colon-targeted drug delivery systems (CTDDS) has gained considerable attention for achieving localized drug action directly at the inflamed colonic region. Colon targeting improves therapeutic efficacy, reduces systemic toxicity, minimizes drug degradation, and enhances patient compliance.[3]



Fig: colon-specific drug delivery

Various strategies have been developed for colon-specific drug delivery, including pH-dependent systems, time-dependent systems, pressure-controlled systems, prodrug approaches, microflora-activated systems, osmotic-controlled systems, and bioadhesive drug delivery systems.[4] Among these approaches, microflora-triggered and polysaccharide-based systems are widely investigated for their ability to undergo enzymatic degradation by colonic bacteria, thereby enabling site-specific drug release.[5] Recent advancements in pharmaceutical technology and nano medicine have further improved the performance of CTDDS. Novel carriers such as nanoparticles, liposomes, microspheres, hydrogels, dendrimers, and biodegradable polymeric systems have demonstrated enhanced drug stability, controlled release, improved mucosal penetration, and prolonged therapeutic action in IBD treatment.[6] Additionally, the use of biodegradable and stimuli-responsive polymers has shown promising results for achieving targeted and sustained drug delivery in inflamed colonic tissues. Despite these advances, several challenges still remain in the development of effective colon-targeted systems, including variations in gastrointestinal pH, transit time, enzymatic activity, mucus barrier penetration, formulation stability, and patient-to-patient variability.[7] Therefore, continuous research and development are required to optimize delivery systems and improve the therapeutic management of inflammatory bowel disease. The present review focuses on the pathophysiology of IBD, various approaches employed in colon-targeted drug delivery systems, recent advancements in nanocarrier-based formulations, evaluation methods, challenges, and future perspectives associated with localized treatment of inflammatory bowel disease.[8]

II. INFLAMMATORY BOWEL DISEASE: PATHOPHYSIOLOGY AND TREATMENT CHALLENGES

Inflammatory bowel disease (IBD), which primarily includes ulcerative colitis and Crohn's disease, is a chronic inflammatory disorder of the gastrointestinal tract. The exact cause of IBD remains unclear; however, it is widely recognized that the disease results from a complex interaction of genetic, immunological, environmental, microbial, and epithelial factors. These interconnected mechanisms contribute to persistent intestinal inflammation and tissue damage.[9]

Genetic susceptibility plays a crucial role in the development of IBD. Numerous genetic studies have identified several susceptibility genes associated with the disease, including NOD2, ATG16L1, and IL23R. Individuals carrying these genetic variations have an increased risk of developing abnormal immune responses toward intestinal microorganisms. However, genetic predisposition alone is insufficient to cause the disease, indicating that additional factors are involved in disease initiation and progression.[10]

A key feature of IBD is dysregulated immune responses. In healthy individuals, the immune system maintains tolerance toward beneficial gut microbes while effectively defending against pathogens. In patients with IBD, this balance is disrupted, leading to excessive activation of immune cells and chronic inflammation. Activated T lymphocytes, macrophages, and dendritic cells release inflammatory mediators that perpetuate tissue injury and impair mucosal healing.[11] Environmental factors also contribute significantly to disease development. Diet, smoking, stress, antibiotic use, urbanization, and exposure to pollutants have all been implicated in increasing the risk of IBD. These factors can alter immune function, affect gut microbial composition, and compromise intestinal barrier integrity, thereby promoting inflammation.[12] Another important contributor is altered gut microbiota, often referred to as dysbiosis. The human colon contains trillions of microorganisms that help maintain intestinal homeostasis. In IBD patients, beneficial bacterial populations are reduced, while potentially harmful bacteria become more abundant. This microbial imbalance can stimulate abnormal immune responses and sustain chronic inflammation. The intestinal barrier serves as a protective interface between luminal contents and underlying tissues. In IBD, impaired intestinal barrier function results in increased permeability, commonly known as a "leaky gut." This allows bacteria, toxins, and antigens to penetrate the intestinal wall, triggering immune activation and exacerbating inflammation.[13]

The inflammatory process in IBD is mediated by several pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-17 (IL-17). These cytokines amplify immune responses, recruit inflammatory cells, and promote tissue destruction. Their central role in disease pathogenesis has made them important therapeutic targets, leading to the development of biologic agents such as anti-TNF therapies. Despite the availability of various treatments, conventional therapies face several limitations. One major challenge is the low concentration of drugs reaching the inflamed colonic tissue, reducing therapeutic effectiveness. Many drugs

also undergo extensive first-pass metabolism in the liver, resulting in decreased bioavailability. Additionally, chronic disease management often requires frequent dosing, which can reduce patient adherence. Conventional systemic administration may lead to adverse effects, including immunosuppression, hepatotoxicity, osteoporosis, and increased susceptibility to infections. Furthermore, the long-term treatment burden contributes to poor patient compliance, negatively affecting clinical outcomes.[14]
These challenges highlight the need for advanced and innovative drug delivery strategies. Colon-targeted drug delivery systems offer the potential to deliver therapeutic agents directly to the inflamed intestinal region, improving local drug concentrations, minimizing systemic exposure, reducing adverse effects, and enhancing overall treatment efficacy in patients with IBD.

III. APPROACHES FOR COLON-TARGETED DRUG DELIVERY

Colon-targeted drug delivery systems (CTDDS) are designed to transport therapeutic agents safely through the upper gastrointestinal tract and release them specifically in the colon. Such systems are particularly beneficial in the treatment of inflammatory bowel disease (IBD), where localized drug delivery can enhance therapeutic efficacy while minimizing systemic side effects. Various approaches have been developed based on the unique physiological characteristics of the colon, including pH, transit time, microbial activity, luminal pressure, and osmotic gradients.[15]



Fig: Approaches for Colon-Targeted Drug Delivery

A. pH-Dependent Systems

pH-dependent systems are among the most widely used approaches for colon targeting. These systems employ enteric polymers that remain intact in the acidic environment of the stomach and the proximal small intestine but dissolve when exposed to the higher pH conditions of the distal ileum and colon. Commonly used polymers include Eudragit S100, Eudragit L100, cellulose acetate phthalate (CAP), and hydroxypropyl methylcellulose phthalate (HPMCP). The drug is coated with these polymers, which protect it during transit through the upper gastrointestinal tract and allow release only when the desired pH is reached. The major advantages of pH-dependent systems are their simplicity, ease of formulation, and widespread commercial acceptance. Several marketed products for ulcerative colitis utilize this approach successfully. However, their effectiveness may be compromised by inter-individual variations in gastrointestinal pH. Additionally, inflammation associated with IBD can alter local pH levels, leading to premature or incomplete drug release.[16]

B. Time-Dependent Systems

Time-dependent drug delivery systems are based on the relatively predictable transit time of dosage forms through the gastrointestinal tract. These formulations are designed with a programmed lag time, after which drug release begins. The lag period is selected to correspond to the average time required for a dosage form to travel from the stomach through the small intestine and reach the colon. An important advantage of this approach is that drug release is independent of pH variations, making it useful in conditions where gastrointestinal pH is unpredictable. However, the reliability of time-dependent systems is affected by variability in gastrointestinal transit times among individuals. Factors such as age, food intake, disease state, and motility disorders can influence transit time. In patients with IBD-associated diarrhea, accelerated intestinal transit may result in premature drug release before reaching the colon.[17]

C. Microflora-Activated Systems

The colon harbors a dense and diverse microbial population capable of producing enzymes that degrade various polysaccharides and azo compounds. Microflora-activated systems utilize natural polymers such as pectin, chitosan, guar gum, dextran, inulin, and amylose as drug carriers. These polymers remain relatively stable in the stomach and small intestine but undergo degradation by bacterial enzymes in the colon, triggering site-specific drug release. This approach offers high specificity and excellent biocompatibility because it exploits the natural metabolic activity of colonic bacteria. Furthermore, many of the polymers used are biodegradable, non-toxic, and inexpensive. Nevertheless, the effectiveness of these systems depends heavily on the composition and activity of the gut microbiota. Since IBD is often associated with microbial dysbiosis, altered bacterial populations may affect the degradation rate of carrier materials and consequently influence drug release.[18]

D. Pressure-Controlled Systems

Pressure-controlled drug delivery systems are designed to respond to the higher luminal pressure generated by colonic peristalsis. These formulations typically consist of capsules coated with pressure-sensitive materials that remain intact during passage through the stomach and small intestine. Upon reaching the colon, increased intraluminal pressure causes mechanical rupture of the coating, releasing the drug. This method offers an alternative mechanism for colon targeting that does not rely on pH or microbial activity. However, its performance may be influenced by variations in colonic motility and pressure patterns among patients, which can affect the timing and extent of drug release.[19]

E. Osmotic-Controlled Systems

Osmotic-controlled systems utilize osmotic pressure as the driving force for drug release. These formulations are engineered to allow water influx through a semi-permeable membrane, creating internal pressure that gradually pushes the drug out through a delivery orifice once the system reaches the colon. Such systems provide controlled and predictable drug release profiles. The primary benefits of osmotic-controlled systems include consistent release kinetics and reduced susceptibility to physiological variations such as pH fluctuations and transit time differences. Consequently, they offer improved reliability and therapeutic performance for colon-targeted drug delivery applications. Together, these approaches represent important strategies for achieving localized treatment of colonic diseases, particularly inflammatory bowel disease.[20]

IV. RECENT ADVANCES IN COLON-TARGETED DRUG DELIVERY

Recent advances in colon-targeted drug delivery systems (CTDDS) have significantly improved the treatment of inflammatory bowel disease (IBD) by enhancing drug localization, increasing therapeutic efficacy, and minimizing systemic adverse effects. Traditional colon-targeting approaches based on pH, transit time, or microbial degradation have shown limitations due to physiological variability among patients. Consequently, researchers have developed advanced delivery platforms that can respond to specific pathological conditions present in inflamed colonic tissues. Among these innovations, smart responsive systems, ligand-mediated targeting, biomimetic nanoparticles, and probiotic-based delivery systems have emerged as promising strategies for precision therapy.[21]



Fig: Recent Advances in Colon-Targeted Drug Delivery

A. Smart Responsive Systems

Smart responsive drug delivery systems are designed to release therapeutic agents only when exposed to specific biological stimuli associated with disease conditions. These systems can respond to changes in pH, enzymatic activity, reactive oxygen species (ROS), and temperature. Since inflamed colonic tissues exhibit distinct biochemical characteristics compared to healthy tissues, these stimuli-responsive carriers can selectively release drugs at the site of inflammation. pH-responsive systems exploit the altered pH environment of the gastrointestinal tract, while enzyme-responsive systems utilize elevated levels of specific enzymes produced by intestinal bacteria or inflammatory cells. Temperature-sensitive systems are engineered to respond to localized increases in tissue temperature that may occur during inflammation. Such intelligent delivery platforms enhance site-specific drug release, reduce premature drug leakage, and improve therapeutic outcomes.[22]

B. ROS-Responsive Carriers

Reactive oxygen species (ROS)-responsive drug delivery systems represent one of the most promising advancements in IBD therapy. Inflamed intestinal tissues produce excessive levels of ROS, including hydrogen peroxide, superoxide radicals, and hydroxyl radicals. These molecules contribute to oxidative stress and tissue damage but also provide an opportunity for targeted drug delivery. ROS-responsive carriers are formulated using materials that undergo degradation or structural changes in the presence of elevated ROS concentrations. When these carriers reach inflamed regions of the colon, the high ROS levels trigger the release of encapsulated drugs directly at the disease site. This targeted approach increases local drug concentration while minimizing systemic exposure. ROS-responsive nanoparticles have shown encouraging results in delivering corticosteroids, anti-inflammatory agents, and biological therapeutics with improved efficacy and reduced toxicity.[23]

C. Ligand-Mediated Targeting

Ligand-mediated targeting is another innovative strategy that enhances the specificity of colon-targeted drug delivery systems. In this approach, nanoparticles are functionalized with ligands capable of recognizing and binding to receptors that are overexpressed on inflammatory cells or damaged intestinal tissues. Commonly used ligands include folic acid, mannose, and hyaluronic acid. Folic acid targets activated macrophages that express folate receptors, while mannose interacts with mannose receptors present on immune cells. Hyaluronic acid binds to CD44 receptors, which are often overexpressed in inflamed colonic tissues. Through receptor-mediated uptake, these ligand-modified carriers can selectively accumulate at sites of inflammation, improving drug delivery efficiency and reducing off-target effects. This approach has demonstrated significant potential in enhancing the therapeutic effectiveness of anti-inflammatory drugs and biologics.[24]

D. Biomimetic Nanoparticles

Biomimetic nanoparticles have emerged as a next-generation drug delivery platform inspired by natural biological systems. These nanoparticles are coated with cell membranes derived from erythrocytes, leukocytes, platelets, or stem cells, allowing them to mimic the properties of natural cells. Cell membrane-coated nanoparticles exhibit several advantages, including immune evasion, enhanced targeting capability, and prolonged circulation time. By disguising themselves as endogenous cells, these carriers can avoid rapid clearance by the immune system and effectively accumulate at inflamed sites. Additionally, membrane proteins present on the coating facilitate interaction with inflammatory tissues, further improving targeting efficiency. Biomimetic nanocarriers have shown promising results in delivering anti-inflammatory agents, nucleic acids, and therapeutic proteins for IBD treatment.[25]

E. Probiotic-Based Delivery Systems

The growing understanding of the gut microbiome has led to the development of probiotic-based drug delivery systems. Engineered probiotic bacteria are being explored as living carriers capable of delivering therapeutic molecules directly to the colon. These microorganisms can colonize the intestinal environment and continuously produce bioactive compounds at the site of inflammation. Researchers have successfully engineered probiotics to express anti-inflammatory proteins, cytokine inhibitors, and gene therapeutics. Such systems offer several advantages, including sustained local drug production, reduced systemic toxicity, and the ability to restore microbial balance in the gut. Although still largely in the experimental stage, probiotic-based therapies represent a highly promising and innovative approach for the long-term management of inflammatory bowel disease.[26]

V. CONCLUSION

Colon-targeted drug delivery systems represent a highly promising approach for the localized treatment of inflammatory bowel disease. By exploiting physiological characteristics of the colon, these systems can enhance therapeutic efficacy while reducing systemic adverse effects. Among the available approaches, microflora-triggered systems, pH-sensitive formulations, and nanoparticle-based carriers have shown considerable potential. Recent advances in smart responsive materials, ligand-mediated targeting, and biomimetic nanotechnology are expected to further improve treatment outcomes. Nevertheless, challenges related to physiological variability, formulation complexity, and clinical translation remain. Continued interdisciplinary research is essential to develop safe, effective, and patient-centered colon-targeted therapies for IBD.

REFERENCES

[1] Anil, K. P., & Philip, B. (2010). Colon targeted drug delivery systems: A review on primary and novel approaches. Oman Medical Journal, 25.

[2] Antonin, K. H., Rak, R., Bieck, P. R., Preiss, R., Schenker, U., Hastewell, J., Fox, R., & Mackay, M. (1996). The absorption of human calcitonin from the transverse colon of man. International Journal of Pharmaceutics, 130(1), 33–39.

[3] Ashford, M., Fell, J. T., Attwood, D., Sharma, H., & Woodhead, P. (1993). An evaluation of pectin as a carrier for drug targeting to the colon. Journal of Controlled Release, 26, 213–220.

[4] Avery, G. S., Davies, E. F., & Brogden, R. N. (1972). Lactulose: A review of its therapeutic and pharmacological properties with particular reference to ammonia metabolism and its mode of action in portal systemic encephalopathy. Drugs, 4(1), 7–48.

[5] Bussemer, T., Otto, I., & Bodmeier, R. (2001). Pulsatile drug-delivery systems. Critical Reviews in Therapeutic Drug Carrier Systems, 18, 433–458.

[6] Calanchi, M., Zema, M., Brunetti, G., & Giorgetti, E. (1999). Timed pulsatile drug delivery systems (U.S. Patent No. 5900252).

[7] Chien, Y. W. (1992). Oral drug delivery and delivery systems. In Y. W. Chien (Ed.), Novel Drug Delivery Systems (pp. 139–196). New York: Marcel Dekker Inc.

[8] Chourasia, M. K., & Jain, S. K. (2003). Pharmaceutical approaches to colon targeted drug delivery systems. Journal of Pharmaceutical Sciences, 6, 33–66.

[9] Evans, D. F., Pye, G., Bramley, R., Clark, A. G., Dyson, T. J., & Hardcastle, J. D. (1988). Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut, 29, 1035–1041.

[10] Fara, J. W. (1989). Colonic drug absorption and metabolism. In L. F. Prescott & W. S. Nimmo (Eds.), Novel Drug Delivery and its Therapeutic Application (pp. 103–120). Chichester: Wiley.

[11] Fukui, E., Miyamura, N., Verma, K., & Kobayashi, M. (2000). Preparation of enteric coated time released press coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. International Journal of Pharmaceutics, 204.

[12] Gazzaniga, A., Iamartino, P., Maffione, G., & Sangalli, M. E. (1994). Oral delayed release system for colonic specific drug delivery. International Journal of Pharmaceutics, 108, 77.

[13] Gliko-Kabir, I., Yagen, B., & Penhasi, A. (1998). Low swelling, crosslinked guar gum and its potential use as a colon-specific drug carrier. Pharmaceutical Research, 15, 1019.

[14] Gurpreet, K., Subheet, J., & Ashok, K. T. (2010). Investigations on microbially triggered system for colon delivery of budesonide. Asian Journal of Pharmaceutical Sciences, 5, 96.

[15] Kopecek, J., Kopeckova, P., Brondsted, H., Rath, R., & Lecek, J. (1992). Polymers for colon-specific drug delivery. Journal of Controlled Release, 19, 121–130.

[16] Kothawade, P. D., Gangurde, H. H., Surawase, R. K., Wagh, M. A., & Tamizharasi, S. (2011). Conventional and novel approaches for colon specific drug delivery: A review. e-Journal of Science and Technology, 6(2), 33–56.

[17] Krishnaiah, Y. S. R., & Satyanarayana, S. (2001). Advances in controlled and novel drug delivery. In N. K. Jain (Ed.), Advances in Controlled and Novel Drug Delivery (pp. 89–119). New Delhi, India.

[18] Kulkarni, S. K. (1999). Pharmacology of gastro-intestinal tract (GIT). In S. K. Kulkarni (Ed.), Book of Experimental Pharmacology (pp. 148–150). New Delhi: Vallabh Prakashan.

[19] Mackay, M., & Tomlinson, E. (1993). Colonic delivery of therapeutic peptides and proteins. In P. R. Bieck (Ed.), Colonic Drug Absorption and Metabolism (pp. 159–176). New York: Marcel Dekker.

[20] McLeod, A. D., Friend, D. R., & Thoma, N. T. (1994). Glucocorticoid-dextran conjugates as

potential prodrugs for colon-specific delivery: Hydrolysis in rat gastrointestinal tract contents. Journal of Pharmaceutical Sciences, 83(9), 1284–1288.

[21] Parul, B. P., & Avinash, S. D. (2011). Multiparticulate approach: An emerging trend in colon specific drug delivery for chronotherapy. Journal of Applied Pharmaceutical Science, 1(5), 59–63.

[22] Philip, A. K., Dubey, R. K., & Pathak, K. (2008). Optimizing delivery of flurbiprofen to the colon using a targeted prodrug approach. Journal of Pharmacy and Pharmacology, 60, 607–613.

[23] Rao, S. S. C., Read, N. W., Bruce, C., Brown, C., & Holdsworth, C. D. (1987). Studies of the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology, 93, 934–940.

[24] Reddy, M. S., Sinha, R. V., & Reddy, D. S. (1999). Colon targeted systems. Drugs Today, 35(7), 537.

[25] Rubinstein, A., Radai, R., Ezra, M., Pathak, S., & Rokem, J. M. (1993). In vitro evaluation of calcium pectinate: A potential colon-specific drug delivery carrier. Pharmaceutical Research, 10, 258.

[26] Philip, A. K., & Philip, B. (2010). Colon targeted drug delivery systems: A review on primary and novel approaches. Oman Medical Journal, 25(2), 79–87.

[27] Choudhary, L., Jain, A., & Agarwal, D. (2020). Colon-targeted oral drug delivery systems: A review. Asian Journal of Pharmaceutical Research and Development, 8(1), 85–90.

[28] Zhang, M., Cui, M., & Liu, K. (2021). Colon-targeted drug delivery of polysaccharide-based nanocarriers for synergistic treatment of inflammatory bowel disease: A review. Carbohydrate Polymers, 272, 118530.

[29] Yang, M., & Merlin, D. (2015). Advances in oral nano-delivery systems for colon-targeted drug delivery in inflammatory bowel disease. Nanomedicine, 11(5), 1117–1132.

[30] Wang, Y., et al. (2024). Design strategies, advances, and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease. Asian Journal of Pharmaceutical Sciences, 19(4), 100943.

[31] Friend, D. R. New oral delivery systems for treatment of inflammatory bowel disease.

[32] Ng, S. C., Shi, H. Y., Hamidi, N., et al. (2017). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century. The Lancet, 390(10114), 2769–2778.

[33] Guan, Q. (2019). A comprehensive review and update on the pathogenesis of inflammatory bowel disease. Journal of Immunology Research, 2019, 7247238.

[34] Vemula, S. K., & Veerareddy, P. R. (2012). Different approaches to design and evaluation of colon-specific drug delivery systems. International Journal of Pharmaceutical Sciences and Nanotechnology, 5(1), 1633–1641.

[35] Chourasia, M. K., & Jain, S. K. (2003). Pharmaceutical approaches to colon-targeted drug delivery systems. Journal of Pharmacy and Pharmaceutical Sciences, 6(1), 33–66.

[36] Amidon, S., Brown, J. E., & Dave, V. S. (2015). Colon-targeted oral drug delivery systems: Design trends and approaches. AAPS PharmSciTech, 16(4), 731–741.

[37] Yang, M., & Merlin, D. (2019). Nanoparticle-mediated drug delivery systems for inflammatory bowel disease therapy. Expert Opinion on Drug Delivery, 16(6), 563–577.

[38] Maroni, A., Del Curto, M. D., Zema, L., et al. (2012). Oral colon delivery of drugs: Technologies and applications. Journal of Drug Delivery Science and Technology, 22(3), 255–264.

[39] Sinha, V. R., & Kumria, R. (2003). Microbially triggered drug delivery to the colon. European Journal of Pharmaceutical Sciences, 18(1), 3–18.

[40] Yang, L., Chu, J. S., & Fix, J. A. (2002). Colon-specific drug delivery: New approaches and in vitro/in vivo evaluation. International Journal of Pharmaceutics, 235(1–2), 1–15.

[41] Friend, D. R. (2005). Colon-specific drug delivery. Advanced Drug Delivery Reviews, 57(2), 247–265.

[42] Chourasia, M. K., & Jain, S. K. Polysaccharides for colon-targeted drug delivery. Drug Delivery.

[43] Takaya, T., Niwa, K., Muraoka, M., et al. (1995). Importance of dissolution process on the systemic availability of drugs delivered by the colon delivery system. Journal of Controlled Release, 33(1), 79–89.

[44] Watts, P. J., & Illum, L. (1997). Colonic drug delivery. Drug Development and Industrial Pharmacy, 23(9), 893–913.
[45] Liu, L., Fishman, M. L., & Hicks, K. B. (2007). pH-sensitive systems for colon-targeted drug delivery. Pharmaceutical Research, 24(3), 491–501.
[46] Rubinstein, A. (1995). Approaches and opportunities in colon-specific drug delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 12(2–3), 101–149.
[47] Andrews, G. P., Laverty, T. P., & Jones, D. S. (2009). Mucoadhesive polymeric platforms for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 71(3), 505–518.
[48] Lehr, C. M. (1994). Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Critical Reviews in Therapeutic Drug Carrier Systems, 11(2–3), 119–160.
[49] Lamprecht, A., Schafer, U., & Lehr, C. M. (2001). Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharmaceutical Research, 18(6), 788–793.
[50] Zhang, M., & Merlin, D. (2018). Nanoparticle-mediated drug delivery systems for inflammatory bowel disease therapy. Expert Opinion on Drug Delivery, 15(9), 843–854.
[51] Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975–999.
[52] Hua, S. (2020). Lipid-based nano-delivery systems for oral drug delivery. Frontiers in Pharmacology, 11, 566.
[53] Peppas, N. A., Bures, P., Leobandung, W., et al. (2000). Hydrogels in pharmaceutical formulations. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 27–46.
[54] Zhang, S., Ermann, J., Succi, M. D., et al. (2015). An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Science Translational Medicine, 7(300), 300ra128.
[55] Aulton, M. E., & Taylor, K. M. G. (2018). Aulton's Pharmaceutics: The Design and Manufacture of Medicines (5th ed.). Elsevier.
[56] Bhushan, B. (2013). Introduction to Tribology (2nd ed.). Wiley.
[57] United States Pharmacopeia. (2020). Uniformity of Dosage Units. In USP 43–NF 38. United States Pharmacopeial Convention.
[58] Jannin, V., Musakhanian, J., & Marchaud, D. (2008). Approaches for the development of solid and semi-solid lipid-based formulations. Advanced Drug Delivery Reviews, 60(6), 734–746.
[59] Maroni, A., Del Curto, M. D., Zema, L., et al. (2012). Oral colon delivery of drugs: Technologies and applications. Journal of Drug Delivery Science and Technology, 22(3), 255–264.
[60] Higuchi, T. (1963). Mechanism of sustained-action medication. Journal of Pharmaceutical Sciences, 52(12), 1145–1149.
[61] Stuart, B. (2004). Infrared Spectroscopy: Fundamentals and Applications. Wiley.
[62] Giron, D. (2002). Applications of thermal analysis and coupled techniques in the pharmaceutical industry. Journal of Thermal Analysis and Calorimetry, 68(2), 335–357.
[63] Brittain, H. G. (1995). Physical Characterization of Pharmaceutical Solids. Marcel Dekker.
[64] Honary, S., & Zahir, F. (2013). Effect of zeta potential on the properties of nano-drug delivery systems. Tropical Journal of Pharmaceutical Research, 12(2), 255–264.
[65] International Council for Harmonisation. (2003). ICH Guideline Q1A(R2): Stability Testing of New Drug Substances and Products.
[66] Cooper, H. S., Murthy, S. N., Shah, R. S., et al. (1993). Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory Investigation, 69(2), 238–249.
[67] Chourasia, M. K., & Jain, S. K. (2003). Pharmaceutical approaches to colon-targeted drug delivery systems. Journal of Pharmacy and Pharmaceutical Sciences, 6(1), 33–66.
[68] Friend, D. R. (2005). Colon-specific drug delivery. Advanced Drug Delivery Reviews, 57(2), 247–265.
[69] Vemula, S. K., & Veerareddy, P. R. (2012). Different approaches to design and evaluation of colon-specific drug delivery systems. International Journal of Pharmaceutical Sciences and Nanotechnology, 5(1), 1633–1641.

[70] Liu, L., Fishman, M. L., & Hicks, K. B. (2007). pH-sensitive systems for colon-targeted drug delivery. Pharmaceutical Research, 24(3), 491–501.
[71] Rubinstein, A. (1995). Approaches and opportunities in colon-specific drug delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 12(2–3), 101–149.
[72] Watts, P. J., & Illum, L. (1997). Colonic drug delivery. Drug Development and Industrial Pharmacy, 23(9), 893–913.
[73] Wang, Y., Liu, S., Li, X., et al. (2024). Design strategies and advances in colon-targeted delivery systems for inflammatory bowel disease treatment. Asian Journal of Pharmaceutical Sciences, 19(4), 100943.